Humuline Regular Cartridge (Insulin Human (Rdna))

Humuline Regular Cartridge is indicated for the management of blood glucose in diabetes mellitus when insulin therapy is required. It is used in both type 1 and type 2 diabetes to provide mealtime coverage and to correct hyperglycemia.

• As basal‑bolus therapy in type 1 diabetes
• As supplemental insulin in type 2 diabetes when oral agents are insufficient
• For correction of high blood glucose levels before meals
• In insulin pump therapy that accepts cartridge‑based rapid‑acting insulin (if compatible)
• For use during pregnancy only under medical supervision

• Insulin human (rDNA) in Humuline Regular Cartridge binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, the insulin signal suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose concentrations. These actions together produce a rapid reduction in post‑prandial blood glucose.

Like other short‑acting insulins, Humuline Regular Cartridge may be associated with adverse reactions that vary in frequency and severity.

Common

• Hypoglycemia (low blood sugar)
• Redness, swelling, or pain at the injection site
• Weight gain
• Lipodystrophy (changes in subcutaneous fat)
• Mild skin rash or itching

Serious

• Severe hypoglycemia leading to loss of consciousness
• Anaphylactic reaction or severe allergic response
• Acute bronchospasm or angioedema
• Persistent hyperglycemia due to insulin resistance

Patients should be aware of specific safety considerations when using Humuline Regular Cartridge.

• Monitor blood glucose regularly to avoid hypoglycemia.
• Adjust dose during illness, stress, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment.
• Discuss pregnancy, lactation, or planned pregnancy with a healthcare professional.
• Store the cartridge according to manufacturer instructions and discard after the recommended period once opened.
• Ensure proper rotation of injection sites to reduce lipodystrophy risk.

Humuline Regular Cartridge can interact with other medicines, affecting its glucose‑lowering action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• MAO‑A inhibitors that can potentiate insulin effects.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose levels.
• Thyroid hormones, which can alter insulin requirements.
• Alcohol, which can cause delayed hypoglycemia.
• Certain diuretics that affect potassium balance.